Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Trex Company, Inc. for possible violations of federal securities laws and other unlawful business practices following disappointing financial results [1][2]. Investigation Details - The investigation is focused on whether Trex has engaged in practices that may have harmed stockholders, particularly in light of recent financial disclosures [2]. Financial Performance - Trex reported Q3 2025 net sales of $285 million, which was 5% below the mid-point of its guidance and a sequential decline of approximately 26% [6]. - The company experienced a 12% decline in net income per share for the nine months ending September 30, 2025, compared to the previous year [6]. - Trex revised its FY 2025 sales growth guidance down to roughly 0% compared to 2024, indicating a "muted" fourth quarter due to expected inventory reductions by pro channel partners [6]. Stock Price Reaction - Following the disappointing Q3 results, Trex's share price fell by $14.61, or about 31.07%, from $47.04 on November 4, 2025, to $32.43 on November 5, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Insperity, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Insperity has engaged in unlawful business practices that may have led to financial losses for investors [2]. Financial Performance - On August 1, 2025, Insperity reported adjusted earnings per share of $0.26, which was a 70% decline year-over-year and missed analyst estimates [6]. - The company attributed its poor performance to higher-than-expected benefits costs, including rising pharmacy expenses and an increase in large insurance claims [6]. - Following the announcement, Insperity's stock price dropped by $14.51, or 24.35%, closing at $45.07 per share on the same day [6]. Next Steps for Investors - Investors who purchased Insperity shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [4].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against James Hardie Industries plc for possible violations of federal securities laws and unlawful business practices [1][2] Company Financial Performance - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit for the period ending June 30, 2025, and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [5] - Following the announcement, James Hardie's American Depositary Receipt (ADR) price fell by $9.79, or 34.44%, closing at $18.64 per ADR on August 20, 2025 [5] Legal and Investor Relations - Investors who suffered losses from purchasing James Hardie shares are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights [1][2] - The law firm offers no-cost consultations for affected investors seeking to learn more about potential claims [2] Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across state and federal courts [3]

Core Viewpoint - BellRing Brands Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following a significant drop in stock price after revealing slowed sales growth expectations [1][2]. Group 1: Company Performance - During the second quarter earnings call on May 6, 2025, BellRing Brands disclosed that certain customers are optimizing their inventories, leading to a forecasted sales growth slowdown to "low-single-digits" for the third quarter [2]. - Following this announcement, BellRing Brands' stock price fell by nearly 19% [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against BellRing Brands on behalf of its stockholders, focusing on possible violations of federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses and is encouraging them to participate in the investigation [3].

Core Viewpoint - The Schall Law Firm is investigating Capricor Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [1][2]. Group 1 - The investigation is centered on whether Capricor issued false or misleading statements or failed to disclose important information to investors [2]. - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Company's BLA for deramiocel [2].